In addition to discussing potential cardiovascular worries associated with Clarus Therapeutics Inc.'s proposed oral testosterone replacement therapy Jatenzo, a US FDA advisory committee also will consider whether the type of tube used to collect samples for dose titration will affect the safe use of the product.
Oral Testosterone Therapy Jatenzo Faces CV, Sampling Tube Issues At Advisory Cmte
US FDA questions Clarus product's long-term safety in briefing documents for Bone, Reproductive and Urologic Drugs Advisory Committee meeting.
